Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'bax inhibitor peptide negative control'

Search results for: 'bax inhibitor peptide negative control'

Items 21-30 of 65

Page
per page
  1. K-252c
    A8344 K-252c
    Target: PKC|PKA
    Summary: Protein kinase inhibitor
      insoluble in EtOH; insoluble in H2O; ≥15.55 mg/mL
  2. SID 26681509
    A4424 SID 26681509
    Target: Cathepsins
    Summary: Human cathepsin L inhibitor,potent and reversible
      <26.98 mg/mL
  3. Dabrafenib (GSK2118436)
    B1407 Dabrafenib (GSK2118436)
     3 Citation
    Target: Raf
    Summary: Inhibitor of BRAF(V600) mutants
      ≥26 mg/mL
  4. PF-03814735
    A4128 PF-03814735
    Target: Aurora Kinases
    Summary: Aurora A/B inhibitor
      Soluble in DMSO
  5. Otamixaban
    A3690 Otamixaban
    Target: Factor Xa
    Summary: Direct factor Xa inhibitors,potent and selective
      ≥22.35 mg/mL
  6. LDN 57444
    A4003 LDN 57444
    Target: UCH
    Summary: UCH-L1 inhibitor,reversible competitve
      insoluble in EtOH; insoluble in H2O; ≥16.7 mg/mL
  7. SC-514
    B1585 SC-514
    Summary: ATP-competitive IKK-2 inhibitor, orally active
      insoluble in EtOH; insoluble in H2O; ≥50.4 mg/mL
  8. GSK1059615
    B2176 GSK1059615
    Target: PI3K|mTOR
    Summary: PI3K and mTOR inhibitor,potent and reversible
      insoluble in EtOH; insoluble in H2O; ≥8.33 mg/mL
  9. Dorsomorphin (Compound C)
    B3252 Dorsomorphin (Compound C)
     5 Citation
    Target: AMPK
    Summary: AMPK inhibitor
      insoluble in H2O; insoluble in EtOH; ≥8.49 mg/mL
  10. Bortezomib (PS-341)
    A2614 Bortezomib (PS-341)
     24 Citation
    Target: Proteasome
    Summary: Proteasome Inhibitor
      insoluble in EtOH; insoluble in H2O; ≥19.21 mg/mL

Items 21-30 of 65

Page
per page
Shop By
Now Shopping by
  1. Reversibility Reversible Remove This Item
Clear All
Shopping Options
Specificity
  1. Selective 54item
Target
  1. Caspases 1 item
  2. Cyclin-Dependent Kinases 2item
  3. Proteasome 3item
  4. Cathepsins 4item
  5. Histone Deacetylases (HDACs) 2item
  6. Akt 1 item
  7. PI3K 2item
  8. CXCR 1 item
  9. Raf 1 item
  10. Aurora Kinases 2item
  11. mTOR 1 item
  12. MMP 1 item
  13. Myosin II ATPases 1 item
  14. Factor Xa 1 item
  15. PLK 1 item
  16. Chk 1 item
  17. JNK 1 item
  18. MEK 1 item
  19. Deubiquitinating enzymes (DUBs) 1 item
  20. Src 1 item
  21. NMDA Receptors 1 item
  22. Microtubules/Tubulins 2item
  23. EGFR 2item
  24. FAK 3item
  25. JAK 2item
  26. Syk 1 item
  27. AMPK 1 item
  28. S-nitrosoglutathione reductase 1 item
  29. CFTR 1 item
  30. thrombin 1 item
  31. ErbB 2item
  32. Actin 1 item
  33. ERK 1 item
  34. PKC 1 item
  35. Calpains 1 item
  36. SMYD2 1 item
  37. RAD51 1 item
  38. Trypsins 1 item
  39. Pyk2 3item
  40. Insulin and Insulin-like Receptors 1 item
  41. ALK 1 item
  42. GTPases 1 item
  43. CETP 1 item
  44. PKA 1 item
  45. Myosin light chain kinases (MLCKs) 1 item
  46. MK2 1 item
  47. ATM/ATR 1 item
  48. AChE 1 item
  49. ZAP-70 1 item
  50. Catechol O-Methyltransferase (COMT) 1 item
  51. DPP-4 1 item
  52. Dipeptidyl-peptidase II 1 item
  53. P97 ATPase 1 item
  54. Aromatases 1 item
  55. UCH 1 item
  56. MST 1 item
  57. ATM 1 item
Reported Experiments
  1. Animal Experiments 54item
  2. Cell Experiments 34item
Related Disease
  1. Acute Myelogenous Leukemia 1 item
  2. Acute Myeloid Leukemia 1 item
  3. Breast Cancer 9item
  4. Cancer 28item
  5. Colon Cancer 3item
  6. Colorectal Cancer 2item
  7. Diabetes 1 item
  8. Glioblastoma 1 item
  9. Glioma 1 item
  10. Hepatocellular Carcinoma 2item
  11. Hypercholesterolemia 1 item
  12. Inflammatory Diseases 2item
  13. Leukemia 2item
  14. Lung Cancer 2item
  15. Lymphoma 1 item
  16. Mantle Cell Lymphoma 1 item
  17. Multiple Myeloma 1 item
  18. Pancreatic Cancer 4item
  19. Psoriasis 1 item
  20. Renal Cancer 1 item
  21. Rheumatoid Arthritis 1 item